Athira Pharma Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athira Pharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Athira Pharma.

4 Wall Street analysts have issued 12-month target prices for Athira Pharma's stock. Their forecasts range from $30.00 to $53.00. On average, they anticipate Athira Pharma's share price to reach $42.50 in the next twelve months. This suggests a possible upside of 135.3% from the stock's current price.
View analysts' price targets for Athira Pharma.

Some companies that are related to Athira Pharma include Xencor (XNCR), Karuna Therapeutics (KRTX), Mediclinic International (MDC), Seres Therapeutics (MCRB), Progyny (PGNY), Silk Road Medical (SILK), Pacific Biosciences of California (PACB), Cantel Medical (CMD), Cantel Medical (CMD), Revolution Medicines (RVMD), Aurinia Pharmaceuticals (AUPH), ADC Therapeutics (ADCT), Madrigal Pharmaceuticals (MDGL), Corcept Therapeutics (CORT) and Editas Medicine (EDIT).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Athira Pharma investors own include GW Pharmaceuticals (GWPH), Intel (INTC), Lumentum (LITE), NIO (NIO), NVIDIA (NVDA), The Boeing (BA), Alibaba Group (BABA), Beyond Meat (BYND), Delta Air Lines (DAL) and Extreme Networks (EXTR).

(ATHA) raised $160 million in an IPO on Friday, September 18th 2020. The company issued 10,000,000 shares at $15.00-$17.00 per share. Goldman Sachs, Jefferies and Stifel acted as the underwriters for the IPO and JMP Securities was co-manager.

Athira Pharma trades on the NASDAQ under the ticker symbol "ATHA."

Athira Pharma's quiet period expired on Wednesday, October 28th. Athira Pharma had issued 12,000,000 shares in its IPO on September 18th. The total size of the offering was $204,000,000 based on an initial share price of $17.00. During the company's quiet period, insiders and underwriters involved in the IPO were prevented from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Shares of ATHA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ATHA stock can currently be purchased for approximately $18.06.

Athira Pharma has a market capitalization of $556.61 million.